ClinicalTrials.gg
CompletedNCT03508856Updated Apr 26, 2018

Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin

An interventional study of Ingenol Mebutate (Picato®) 0.015% gel in Actinic Keratosis and Photo-aged Skin, sponsored by Skin Laser & Surgery Specialists. Completed. Open to participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-26.

Sponsored by Skin Laser & Surgery Specialists · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2015, registered May 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing ingenol mebutate in Keratosis, Actinic — none open to participants now, none under way, none of them phase 3. ingenol mebutate · Keratosis, Actinic.

Enrollment
36th of 43
23 · median 100
Started
2015
with 6 others
No phase
2 of 43
none open now
Registered
40th of 43
by date
Lead sponsor
1 of 43
Skin Laser & Surgery Specialists

Among the 43 studies testing ingenol mebutate in Keratosis, Actinic, this one is the 36th largest by enrollment, is one of 7 that started in 2015, is one of 2 with no phase, and was the 40th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

None of the 43 studies testing ingenol mebutate in Keratosis, Actinic is open now. The open studies under Keratosis, Actinic, anywhere →

About ingenol mebutate

ingenol mebutate: first FDA approval 2012 (PICATO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies testing ingenol mebutate in Keratosis, Actinic as a file.
02

Study summary

Clinical Evaluation:

Subjects having actinic keratoses and meeting Glogau Photoaging Class III or IV complete the FDA approved 3 day course of Picato® 0.015% gel as approved for the treatment of facial Actinic Keratosis. Each subject undergoes clinical multiple-angle standardized photographs on day 1, day 7, day 30, and day 60. Full face photography will be obtained with the medical research digital camera. Both subjects and investigators complete questionnaires at each visit with individual questions regarding improvement in actinic keratoses and overall skin appearance, wrinkling, dyschromia, erythema, and textural quality of skin. Each characteristic listed above will be graded on a 5 point scale ranging from 0 (lowest quality/worst appearance) to 5 (highest quality/best appearance). In addition, investigators will examine the subject's face and assign a numeric assessment on a 9 point scale ranging from 0 to 8 using previously published verified Griffiths' Photonumeric Photoaging scale. A second and third investigator will be presented at random blinded pretreatment (day 0) and posttreatment (day 60) photographs of each subject and be asked to assign a numerical value from Griffiths' Photonumeric Photoaging Scale. These blinded investgators will be given no information regarding which day each photograph represents. Comparison will be made of skin quality questionnaire scores from each visit and the pre and post treatment Griffiths' Photonumeric Grades.

The investigator opted against a split-face study design given the difficulty of blinding with this type of study as well as difficulty recruiting subjects willing to treat for two separate courses.

Histologic Evaluation:

Standard 3mm dermatology punch biopsies from clinically sun damaged skin will be taken. Biopsy will be taken from either the cosmetically acceptable pre-or infra-auricular area. A digital photograph will be taken and used to identify the pre-treatment biopsy site. Biopsies will be taken of 5 subjects before treatment and at day 60. Day 60 biopsies will be taken immediately adjacent to previously photographed and identified pre-treatment biopsies. Biopsies will be stained with hematoxylin and eosin and histologic features of pre and post treatment skin will be evaluated. Measurement of actinic keratoses, solar elastosis and overall epidermal and dermal thickness pre and post treatment will be compared.

03

Conditions studied

  • Actinic Keratosis
  • Photo-aged Skin

Browse trials for

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be adults aged 45-75 years of age.
  • Subjects must be in good general health as confirmed by the medical history.
  • Subjects must be able to read, sign, and understand the .
  • Subjects must meet the criteris for Glogau Photoaging class III or class IV.
  • Subjects have a diagnosis of actinic keratosis.
  • Subjects must be willing to apply Picato 0.015% gel
  • Subjects must be willing to forego any other treatments on the face, including cosmetic treatments, tanning bed use, and excessive sun exposure while enrolled in the study.
  • If a subject is a female of she must have a urine pregnancy test result prior to study treatment initiation and must agree to use an approved method of while enrolled in the study.

Exclusion criteria

Exclusion Criteria:

-. Subjects with a history of melanoma anywhere on the body.

  • Subjects with any unstable medical condition as determined by the clinical investigator.
  • Subjects with untreated non-melanoma skin cancer on the face or within the treatment area.
  • Subjects with dermatitis or any dermatologic disease in the treatment area that would obscure the evaluation of photoaging parameters.
  • Subjects who have undergone any form of 'field treatment' including 5-fluorouracil, photodynamic therapy, or ingenol mebutate in the preceeding six months.
  • Women who are pregnant, lactating, or planning to become pregnant during the study period.
  • Subjects who have experienced a major medical event (including stroke, heart attack, etc) within 90 days of starting the study.
  • Subjects who have active substance abuse disorders.
  • Subjects who have known allergies to any components of the study drug.
  • Subjects who are currently particpating in another clinical trial or who have completed a study involving laser, systemic, or topical treatment of the face within 30 days prior to study treatment initiation.
  • Subjects who have received any of the following within 90 days prior to study treatment initiation:
  • Interferon or interferon inducers
  • Cytotoxic drugs
  • Immunomodulators or treatments (except inhaled or intranasal )
  • Oral or parenteral corticosteroids
  • Topical steroids to treatment area
  • Any dermatologic procedures or surgeries to the treatment area, including cryosurgery for AKs
  • Subjects who have used any topical prescription medications on the study area within 30 days prior to study treatment initiation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Picato 0.015% gel

    Picato 0.015% gel, is a topical treatment for actinic ketatoses.

    Drug: Ingenol Mebutate (Picato®) 0.015% gel

06

What researchers measure

Primary outcomes

  1. To evaluate the improvement in actinic keratoses and photoaged skin as measured numerically by Griffiths' Photonumeric Photoaging scale and questionnaires,

    Time frame: 60 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Aug 2016, 9 months.

Of 33 interventional studies with no phase under Keratosis, Actinic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 33. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2016
First posted
Apr 26, 2018
StartActual
Nov 9, 2015
Primary completionActual
Aug 9, 2016
CompletionActual
Aug 9, 2016
Last update
Apr 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03508856
Lead sponsor
Skin Laser & Surgery Specialists
Collaborators
LEO Pharma
Responsible party
David J. Goldberg, MD (MD, Skin Laser & Surgery Specialists) — Principal investigator
First posted
Apr 26, 2018
Start date
Nov 9, 2015
Primary completion
Aug 9, 2016
Completion
Aug 9, 2016
Last update
Apr 26, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ingenol mebutate

Start the discussion